While no KDMi has been approved for the treatment of cancer patients so far, clinical trials evaluating the effects of several LSD1 or KDM4 inhibitors are under way [8], and clinical oncology may be approaching the inclusion of KDMi into the anti-cancer therapeutic armamentarium. This evidence concerns the gene KDM1A and cancer.